Furthermore, understanding how systemic conditions (e.g., diabetes or osteoporosis, etc.)influence YAP activation may allow for the customization of therapeutic approaches, particularly for populations with impaired healing capabilities. The gene discussed is YAP1; the disease is diabetes mellitus.